Intellia Therapeutics, Inc..
NTLA.US | Research and experimental development on natural sciences and engineering
Intellia Therapeutics, Inc. is a biotechnology company focused on the development of therapeutics utilizing CRISPR/Cas9 technology. The company is pioneering the development of potentially curative gene editing therapies for genetic diseases. Intellia's programs focus on liver-directed therapies, ex...Show More
Better Health for All
-30
Intellia Therapeutics' core business is developing potentially curative gene-editing treatments for severe genetic diseases, with 100% of its portfolio focused on revolutionary health benefits.
1
Clinical trials for hereditary angioedema (HAE) showed a 98% mean reduction in monthly HAE attack rate, and for ATTR amyloidosis, NTLA-2001 led to an 87% mean reduction in serum TTR protein concentration.
2
The company has no revenue from products with negative health outcomes. However, the FDA imposed clinical holds on two trials in October 2025 due to a Grade 4 liver transaminase elevation in one patient, though the hold on one trial was later lifted after mitigation measures.
3
The company's expanded access policy states it does not provide access to investigational therapies outside of clinical trials, and it does not provide pricing information.
4
While Intellia partners with patient advocacy groups and aims for diverse clinical trials, it does not provide specific data on the percentage of vulnerable populations reached.
5
The company discloses clinical trials on public databases and discusses risks in press releases.
6
Intellia is a clinical-stage genome editing company, with its entire R&D focused on health improvement.
7
The company has a small ecological footprint and provides vitamin A supplementation to compensate for TTR loss.
8
Intellia offers an employee assistance program and mental wellbeing benefits to its employees but does not detail broader mental health initiatives.
9
The company's expanded access policy reserves the right to revise it in accordance with the 21st Century Cures Act, but it does not offer patent flexibility or licensing in low-income countries.
10
Clinical trials are conducted with informed consent and oversight from ethics committees, but diversity in trial populations is not quantified.
11
Intellia aims to work with communities to increase health literacy and awareness of clinical trials.
12
Fair Money & Economic Opportunity
0
Intellia Therapeutics is a pre-commercial biotechnology company focused on developing therapeutics, not a financial institution.
1
The company does not offer lending, deposit, or other financial services to consumers.
2
Therefore, all KPIs related to financial products, pricing, fees, lending, debt, and customer financial data are not applicable to its core business model.
3
The company does not have a loan/insurance book, generate APRs or fee structures, or manage customer financial data in the context of financial services.
4
While Intellia engages in various DEI, community, and employee benefit initiatives, these do not fall under the scope of financial inclusion or economic opportunity as defined by the rubric's KPIs for financial institutions.
5
Fair Pay & Worker Respect
20
Intellia Therapeutics reported a CEO-to-median employee pay ratio of 47:1 for the 2024 fiscal year.
1
The company's average employee turnover rate in 2022 was 13 percent, which is lower than the 23 percent average for life sciences and medical device companies during the same period.
2
None of the company's employees are covered by collective bargaining agreements.
3
Intellia Therapeutics conducted a pay equity analysis in 2021 by an independent third-party expert and an internal analysis in 2022, both of which did not reveal any pay gaps based on gender, race, or age.
4
The company offers comprehensive medical, dental, and vision insurance, along with disability insurance coverage options, and 100%-paid leave of absence programs.
5
Fair Trade & Ethical Sourcing
0
No specific, concrete data points regarding Intellia Therapeutics' fair trade and ethical sourcing practices, supply chain audits, forced or child labor incidents, traceability, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend were found in the provided articles.
1
The articles explicitly state a lack of relevant quantitative data for NTLA.US.
2
Honest & Fair Business
0
No specific, concrete data points were found in the provided article to assess Intellia Therapeutics, Inc. against any of the 'Honest & Fair Business' KPIs. The article, a PCAOB Form AP filing, primarily details the company's external auditor for the 2023 financial statements but does not provide information on regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage percentages, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policies, or the extent of third-party verification of ethical claims.
1
Kind to Animals
-40
The company conducts preclinical animal studies, including non-human primate (NHP) and rodent models, which are stated as required to assess product safety and activity.
1
It complies with Good Laboratory Practice (GLP) guidelines, including applicable requirements for the humane use of laboratory animals.
2
While in vitro testing is mentioned for liver cell editing, the company also notes that non-human models for targeted diseases may not be appropriate or available, indicating a primary reliance on in vivo animal models for preclinical development.
3
The company's policy adheres to legal mandates for animal testing but does not explicitly prohibit discretionary testing or outline reduction goals beyond regulatory compliance.
4
No War, No Weapons
0
The provided articles for Intellia Therapeutics, Inc. (NTLA.US) focus on the company's financial performance, research and development in genome editing, and clinical trial data. No information is available regarding the company's involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other metrics related to the 'No War, No Weapons' ethical value.
1
Therefore, no KPIs can be scored based on the evidence provided.
Planet-Friendly Business
0
Intellia Therapeutics' 2023 Corporate Responsibility Report and related summaries mention general ESG initiatives, including environmental sustainability efforts like energy-efficient buildings, recycling programs, and transportation benefits.
1
The company also highlights alignment with the Sustainability Accounting Standards Board (SASB) framework.
2
However, the provided articles do not contain any specific quantitative data or concrete facts for any of the planet-friendly business KPIs, such as total greenhouse gas emissions, renewable energy percentage, waste diversion rates, or the existence of science-based targets.
3
Therefore, no KPIs can be scored based on the evidence provided.
Respect for Cultures & Communities
10
Intellia Therapeutics has at least 9 formal partnerships with community groups, including the United Negro College Fund (UNCF), SACNAS, MassBay Community College, OUTbio, Latinos in BIO, Veterans Ascend, The LEAH Project, Science Club for Girls, and Waltham Fields Community Farm.
1
No cultural appropriation incidents have been reported.
2
The company has a Cultural Ambassadors Program
3
and Employee Resource Groups (ERGs) with 33% employee participation,
4
but there is no specific data on the percentage of employees completing cultural sensitivity training.
5
Intellia Therapeutics has raised over $150,000 for the Intellia/UNCF scholarship fund
6
and made over $70,000 in corporate and employee donations to 15+ charitable organizations in 2023,
7
but the percentage of revenue donated to cultural heritage organizations is not specified.
Safe & Smart Tech
0
Intellia Therapeutics provides users with excellent privacy controls, allowing them to request to erase, change, restrict use, or access their personal information.
1
The company supports Global Privacy Control (GPC) signals and allows users to adjust cookie preferences.
2
It also outlines specific rights for California, UK, Swiss, and EEA residents, including data portability.
3
Intellia conducts annual cybersecurity awareness training for employees.
4
The company performs regular system maintenance, including applying security patches, and conducts regular penetration testing.
5
Intellia considers the amount, nature, and sensitivity of personal information, potential harm from unauthorized use, processing purposes, and applicable legal requirements to determine appropriate data retention periods.
6
The company states its compliance with federal and state data privacy, security, fraud, and abuse laws in the U.S., as well as similar foreign laws, including the California Consumer Privacy Act (CCPA), General Data Protection Regulation (GDPR), and UK GDPR.
7
The 2023 Corporate Responsibility report aligns with the Sustainability Accounting Standards Board (SASB) framework.
8
Zero Waste & Sustainable Products
-30
Intellia Therapeutics has implemented several waste reduction initiatives, including single-stream recycling at its second largest building and dual-stream recycling at all other buildings.
1
The company uses recyclable batteries and fluorescent/LED bulbs, offers composting services, and has removed plasticware.
2
Additionally, beverage machines have been installed to reduce or eliminate aluminum can or pod usage, and a Wellness & Sustainability team celebrates Earth Day annually to promote green initiatives.
3
For hazardous waste, the company's operations involve hazardous and flammable materials, and it generally anticipates contracting with third parties for the disposal of these materials and wastes.
4